Tabriz University of Medical Sciences, Tabriz, Iran.
Integr Cancer Ther. 2013 Nov;12(6):496-502. doi: 10.1177/1534735413485417. Epub 2013 Apr 30.
The aims of this study were to determine the effect of conjugated linoleic acid (CLA) supplementation on inflammatory factors and matrix metalloproteinase (MMP) enzymes in rectal cancer patients undergoing chemoradiothetrapy.
In this randomized, double-blind, placebo-controlled pilot study, 34 volunteer patients with rectal cancer undergoing chemoradiotherapy assigned into the CLA group (n = 16), receiving 3 g CLA/d, and placebo group (n = 18) receiving placebo capsules (sunflower oil) for 6 weeks. The supplementation began 1 week before starting RT (loading period) and continued every day during treatment. Before and after intervention, serum tumor necrosis factor α (TNF-α), interleukin 1β (IL-1β), IL-6, MMP-2, MMP-9, and high-sensitivity C-reactive protein (hsCRP) were measured by enzyme-linked immunosorbent assay (ELISA) kits and immunoturbidimetric method, respectively. Independent t tests and paired t tests were used to compare parameters between and within groups, respectively.
In the CLA group, the mean serum TNF-α, IL-1β, hsCRP, MMP-9, and MMP-2 levels reduced insignificantly. However, significant changes in TNF-α (P = 0.04), hsCRP (P = 0.03), and MMP-9 (P = 0.04) concentrations were observed in the CLA group when compared with the placebo group. The mean serum IL-6 level remained unchanged in the CLA group but increased remarkably in the placebo group.
According to our results, CLA supplementation improved inflammatory factors, MMP-2, and MMP-9 as biomarkers of angiogenesis and tumor invasion. It seems that CLA may provide new complementary treatment by reducing tumor invasion and resistance to cancer treatment in patients with rectal cancer.
本研究旨在探讨共轭亚油酸(CLA)补充剂对接受放化疗的直肠癌患者炎症因子和基质金属蛋白酶(MMP)的影响。
这是一项随机、双盲、安慰剂对照的初步研究,34 名接受放化疗的直肠癌志愿者患者被分为 CLA 组(n=16),每天服用 3 克 CLA;安慰剂组(n=18)接受安慰剂胶囊(葵花籽油),为期 6 周。补充剂在开始放射治疗前 1 周开始(加载期),并在治疗期间每天服用。干预前后,通过酶联免疫吸附试验(ELISA)试剂盒和免疫比浊法分别检测血清肿瘤坏死因子-α(TNF-α)、白细胞介素 1β(IL-1β)、IL-6、MMP-2、MMP-9 和高敏 C 反应蛋白(hsCRP)。采用独立 t 检验和配对 t 检验分别比较组间和组内参数。
CLA 组患者血清 TNF-α、IL-1β、hsCRP、MMP-9 和 MMP-2 水平无显著降低。然而,与安慰剂组相比,CLA 组 TNF-α(P=0.04)、hsCRP(P=0.03)和 MMP-9(P=0.04)浓度有显著变化。CLA 组患者血清 IL-6 水平保持不变,但安慰剂组显著增加。
根据我们的结果,CLA 补充剂改善了炎症因子、MMP-2 和 MMP-9,这些因子是血管生成和肿瘤侵袭的生物标志物。CLA 可能通过降低肿瘤侵袭和对直肠癌患者的癌症治疗的耐药性,提供新的补充治疗方法。